S&P 500 Healthcare Sector SEC Filings — July 21, 2026

Revenue grew 18.5% YoY to $2.89B, operating income surged 30.7% YoY to $972M, and gross margin expanded 150 bps to 67.8% — all well above sector averages

Aggressive share repurchases of $1.44B in H1 2026 (vs $181M in H1 2025, +697% YoY) signal strong management confidence and shareholder return focus

Net earnings jumped 57% YoY to $870M in Q2 2026, with non-GAAP adjusted diluted EPS up 8.0% to $1.94, beating expectations

Full-year 2026 adjusted EPS guidance raised to $8.45-$8.60 from $8.35-$8.55, indicating sustained profitability

SG&A expenses decreased 12.2% YoY to $2.07B, driving operating leverage and margin improvement

EVP Broadhurst Vanessa sold $5.79M in stock after exercising options at much lower prices (~$130 vs $251 sale), a classic insider profit-taking pattern that may signal peak valuation concerns

Q3 2026 core revenue guidance of 2.0%-3.0% YoY is below Q2's 3.0% actual, signaling a potential growth slowdown

Bioprocessing revenue impacted by customer project timing, creating near-term revenue headwinds

Routine director stock awards (4-14 shares each) are non-material and do not indicate insider conviction either way

13F portfolio heavily tilted toward tech (Apple, Amazon, Alphabet, Broadcom) with only modest healthcare exposure, suggesting cautious sector allocation

Q3 core revenue guidance of 2.0%-3.0% is below Q2's 3.0% actual, and full-year guidance of 3.0%-4.0% implies H2 slowdown — watch for further cuts

Cash and equivalents fell to $4.35B from $4.62B at year-end 2025, partly due to a $9.84B acquisition, increasing balance sheet leverage

Interest expense rose 50.7% YoY to $107M in Q2 2026, reflecting higher debt from the large acquisition

Total comprehensive income fell sharply to $668M from $1.60B in the prior-year quarter due to unfavorable foreign currency translation adjustments, highlighting FX exposure

EVP sold 23,054 shares for $5.79M, reducing holdings to 23,003 shares — a significant reduction that could indicate lack of confidence at current valuation

Cash and equivalents declined to $2.76B from $3.37B at year-end 2025, driven by $1.44B in buybacks — while shareholder-friendly, it reduces financial flexibility

Customer project timing impacted bioprocessing revenue, a key growth driver, creating unpredictability in a core segment

No insider buying or selling beyond routine director awards — lack of insider conviction could be interpreted as neutral-to-cautious

Gross margin expanded 150 bps YoY to 67.8% and operating margin improved to 33.6% from 30.5% — continued operating leverage offers upside to estimates

$1.44B in H1 2026 buybacks (5.3% of market cap at current prices) provide strong EPS support and signal management's view of undervaluation

The $9.84B acquisition closed in H1 2026 should drive revenue and cost synergies in H2 2026 and 2027, with SG&A already declining 12.2% YoY

Interest income surged to $61M in Q2 2026 from $8M a year ago (+662.5%), providing a non-operational earnings boost

Bioprocessing orders grew mid-teens in Q2 2026, signaling strong future demand despite current revenue timing issues

The $5.79M insider sale may create a buying opportunity if fundamentals remain strong — J&J's diversified healthcare model provides downside protection

Portfolio reveals $485.8M in equities with top tech holdings — investors can track Cigna's sector rotation for healthcare allocation clues

18.5% YoY revenue growth in Q2 2026 outpaces most healthcare peers, driven by robotic surgery adoption — secular growth story intact

Intuitive Surgical's gross margin expanded 150 bps YoY while Danaher's SG&A cuts drove operating leverage — companies with pricing power and cost controls are outperforming peers [IMPLICATION: Favor companies with demonstrated margin expansion]

Intuitive Surgical's buybacks surged 697% YoY to $1.44B, while Danaher completed a $9.84B acquisition — healthcare companies are deploying record cash, but with different strategies (buybacks vs M&A) [IMPLICATION: Monitor execution risk on M&A vs buyback efficiency]

Danaher's Q3 core revenue guidance of 2.0%-3.0% implies deceleration from Q2's 3.0% actual, while Intuitive Surgical's strong Q2 suggests continued momentum — guidance divergence within the sector [IMPLICATION: Prefer companies with accelerating or stable guidance trends]

J&J's EVP sold $5.79M in stock, while Eli Lilly directors received only routine awards — insider activity is skewed toward selling, suggesting caution at current valuations [IMPLICATION: Monitor insider selling patterns for broader sector sentiment]

Danaher's comprehensive income fell 58% due to FX translation, and interest expense rose 51% — healthcare companies with international exposure and debt are facing macro headwinds [IMPLICATION: Favor domestic-focused or low-leverage healthcare names]

Watch for core revenue growth to confirm or refute the 2.0%-3.0% guidance — any miss could trigger sell-off; earnings call expected late October 2026

Monitor if the aggressive $1.44B H1 buyback pace continues into H2 — slowdown could signal management's view of fair valuation

Watch for additional insider selling by other executives — a pattern of multiple C-suite sales would be a strong bearish signal

Track integration progress of the $9.84B acquisition — any impairment or synergy miss could pressure the stock

While current awards are routine, any material insider buying or selling would be a significant signal given the stock's high valuation

Next 13F filing (due Nov 15, 2026) will reveal Q3 portfolio shifts — watch for increased healthcare exposure as a sector call

Mid-teens order growth in Q2 should convert to revenue in H2 2026 — monitor for confirmation of demand recovery

Cash declined to $2.76B from $3.37B — watch for further drawdown if buybacks continue at current pace